Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:anticoagulant
coumarin derivative |
| gptkbp:antidote |
gptkb:vitamin_A
|
| gptkbp:ATCCode |
gptkb:B01AA03
|
| gptkbp:bioavailability |
nearly 100%
|
| gptkbp:brand |
gptkb:Coumadin
gptkb:Jantoven |
| gptkbp:CASNumber |
129-06-6
|
| gptkbp:contraindication |
pregnancy
bleeding disorders |
| gptkbp:discoveredBy |
gptkb:Karl_Paul_Link
|
| gptkbp:discoveredIn |
1940s
|
| gptkbp:eliminationHalfLife |
20-60 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C19H15NaO4
|
| https://www.w3.org/2000/01/rdf-schema#label |
warfarin sodium
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
vitamin K antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
gptkb:X_(US)
|
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting bleeding bruising |
| gptkbp:synonym |
Sodium warfarin
Warfarin sodium salt |
| gptkbp:UNII |
5Q7ZVV76EI
|
| gptkbp:usedFor |
prevention of thromboembolism
prevention of thrombosis |
| gptkbp:bfsParent |
gptkb:Marevan
|
| gptkbp:bfsLayer |
6
|